Definiens – The tissue phenomics company
AstraZeneca and its research and development division, MedImmune, acquired Definiens
Definiens’ technology provides detailed tissue biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information, an approach known as Tissue Phenomics. The system reportedly improves the search for biomarkers in cancer tissues by measuring important variables within the sample, such as the location, identity and interaction between key constituents.
Industry
Digital Health
Case facts
Location
Switzerland
Status
Exit June 2014